[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1660 Enrolled Bill (ENR)]

        H.R.1660

                     One Hundred Fifteenth Congress

                                 of the

                        United States of America


                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
           the third day of January, two thousand and eighteen


                                 An Act


 
      To direct the Administrator of the United States Agency for 
    International Development to submit to Congress a report on the 
   development and use of global health innovations in the programs, 
                 projects, and activities of the Agency.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``Global Health Innovation Act of 
2017''.
SEC. 2. ANNUAL REPORT.
    (a) In General.--Not later than 180 days after the date of the 
enactment of this Act, and annually thereafter for a period of 4 years, 
the Administrator of the United States Agency for International 
Development shall submit to Congress a report on the development and 
use of global health innovations in the programs, projects, and 
activities of the Agency.
    (b) Matters To Be Included.--The report required by subsection (a) 
shall include the following:
        (1) A description of--
            (A) the extent to which global health innovations described 
        in subsection (a) include drugs, diagnostics, devices, 
        vaccines, electronic and mobile health technologies, and 
        related behavior change and service delivery innovations;
            (B) how innovation has advanced the Agency's commitments to 
        achieving an HIV/AIDS-free generation, ending preventable child 
        and maternal deaths, and protecting communities from infectious 
        diseases, as well as furthered by the Global Health Strategic 
        Framework;
            (C) how goals are set for health product development in 
        relation to the Agency's health-related goals and how progress 
        and impact are measured towards those goals;
            (D) how the Agency's investments in innovation relate to 
        its stated goals; and
            (E) progress made towards health product development goals.
        (2) How the Agency, both independently and with partners, 
    donors, and public-private partnerships, is--
            (A) leveraging United States investments to achieve greater 
        impact in health innovation;
            (B) engaging in activities to develop, advance, and 
        introduce affordable, available, and appropriate global health 
        products; and
            (C) scaling up appropriate health innovations in the 
        development pipeline.
        (3) A description of collaboration and coordination with other 
    Federal departments and agencies, including the Centers for Disease 
    Control and Prevention, in support of global health product 
    development, including a description of how the Agency is working 
    to ensure critical gaps in product development for global health 
    are being filled.
        (4) A description of how the Agency is coordinating and 
    aligning global health innovation activities between the Global 
    Development Lab, the Center for Accelerating Innovation and Impact, 
    and the Bureau for Global Health.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.